NRSN
NeuroSense Therapeutics Ltd

3,589
Mkt Cap
$22.87M
Volume
116,778.00
52W High
$2.60
52W Low
$0.63
PE Ratio
-1.25
NRSN Fundamentals
Price
$0.731
Prev Close
$0.77
Open
$0.76
50D MA
$0.8885
Beta
0.76
Avg. Volume
175,809.18
EPS (Annual)
-$0.5489
P/B
6.57
Rev/Employee
$0.00
$18.98
Loading...
Loading...
News
all
press releases
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data...
PR Newswire·4d ago
News Placeholder
More News
News Placeholder
PrimeC New Data to Be Presented at AD/PD 2026 Conference
PrimeC New Data to Be Presented at AD/PD 2026 Conference PrimeC New Data to Be Presented at AD/PD 2026 Conference PR Newswire CAMBRIDGE, Mass., March 18, 2026 Dr. Christian Lunetta to Present 'From...
PR Newswire·10d ago
News Placeholder
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity JAMA Neurology Publishes Results from PARADIGM Phase...
PR Newswire·12d ago
News Placeholder
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference PR Newswire CAMBRIDGE...
PR Newswire·19d ago
News Placeholder
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS NeuroSense Announces Statistically Significant 65...
PR Newswire·1mo ago
News Placeholder
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering...
PR Newswire·2mo ago
News Placeholder
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease PR Newswire CAMBRIDGE, Mass., Jan. 21, 2026 Patent protection...
PR Newswire·2mo ago
News Placeholder
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB PR Newswire CAMBRIDGE, Mass., Jan. 8, 2026...
PR Newswire·3mo ago
News Placeholder
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study PR...
PR Newswire·3mo ago
News Placeholder
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 PR Newswire CAMBRIDGE, Mass., Dec. 4, 2025 CAMBRIDGE, Mass...
PR Newswire·4mo ago
<
1
2
...
>

Latest NRSN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.